within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B03A_IronPreparations.B03AB05_FerricOxidePolymaltoseCo;

model FerricOxidePolymaltoseCo
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.1,
    Cl = 8.333333333333333e-08,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.005,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0003333333333333333,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>FerricOxidePolymaltoseComplexes</td></tr><tr><td>ATC code:</td><td>B03AB05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.3</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ferric oxide polymaltose complex is an iron-carbohydrate complex used in the treatment of iron deficiency anemia. It is used as a source of iron for patients who cannot tolerate or do not respond to oral iron therapy. The drug is currently approved and is used in clinical practice, mainly administered orally or intravenously.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for adult population after oral administration, as no direct, comprehensive PK studies have been published for this drug complex.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B03AB05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end FerricOxidePolymaltoseCo;
